Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S.
IRVINE, Calif.--(BUSINESS WIRE)--Jan. 15, 2026--
Henry Schein, Inc. (Nasdaq: HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/
CLIA Waived CitoCBC System Designed for On-Site Testing in Urgent Care Centers and Physician Offices.
“We are pleased to join with CytoChip to provide the CitoCBC system to our customers, helping to bring essential lab testing out of the hospital and into the office, with results provided to the patient during their visit,” said Ty Ford, Vice President and General Manager of Sales for Henry Schein Medical. “This collaboration strengthens our commitment to offering healthcare providers products and solutions that increase efficiencies while enhancing patient care.”
The CitoCBC system delivers full CBC results in approximately eight minutes, requires minimal staff training, and provides lab-quality accuracy by miniaturizing advanced fluorescent flow cytometry technology onto a cartridge for use in near-patient settings.
“Partnering with Henry Schein enables us to expand the reach of CitoCBC, assisting healthcare providers in settings such as physician offices, urgent care centers, and pharmacies to access immediate diagnostic data,” said Wendian Shi, PhD, Chief Executive Officer of CytoChip. “Together, we can support more informed diagnostic decisions and improve patients’ access to timely care.”
Henry Schein’s exclusivity in the United States includes ambulatory care settings such as physician offices, urgent care centers, as well as critical access hospitals with 25 patient beds or fewer. The exclusivity does not include long-term care or acute care facilities.
For more information, please visit www.cytochipinc.com.
About CytoChip Inc.
CytoChip Inc. is a diagnostic technology company founded in 2016 by researchers from Caltech and other leading institutions. Headquartered in Irvine, California, the company is dedicated to supporting healthcare providers with data-driven diagnostic solutions designed for near-patient use.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for healthcare professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides more than one million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20260115495488/en/
Sirun@cytochipinc.com
Source: CytoChip Inc.
